[{"id":"499a3418-3780-4d53-819e-a9b110bd48a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990493","created_at":"2021-01-18T19:37:12.031Z","updated_at":"2024-07-02T16:35:43.740Z","phase":"Phase 1","brief_title":"Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma","source_id_and_acronym":"NCT03990493","lead_sponsor":"PrimeVax Immuno-Oncology Inc.","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PV-001-DC • PV-001-DV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-06"},{"id":"7c9b75c3-9f92-43f5-9d62-39a684b29dbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03989895","created_at":"2021-01-18T19:37:02.966Z","updated_at":"2024-07-02T16:35:43.820Z","phase":"Phase 1","brief_title":"Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma","source_id_and_acronym":"NCT03989895","lead_sponsor":"PrimeVax Immuno-Oncology Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" BRAF mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PV-001-DC • PV-001-DV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-06"}]